Global Eosinophilic Asthma Treatment Supply, Demand and Key Producers, 2026-2032
The global Eosinophilic Asthma Treatment market size is expected to reach $ 173693 million by 2032, rising at a market growth of 17.2% CAGR during the forecast period (2026-2032).
Eosinophilic asthma treatment focuses on managing a severe subtype of asthma characterized by elevated levels of eosinophils, a type of white blood cell that contributes to inflammation in the airways. Traditional therapies, such as inhaled corticosteroids and bronchodilators, often prove insufficient for patients with this phenotype. Monoclonal antibodies such as mepolizumab, reslizumab, and benralizumab target interleukin-5 (IL-5) or its receptor, effectively reducing eosinophil levels and decreasing the frequency of exacerbations. The management strategy also includes identifying eosinophilic biomarkers through blood tests or sputum analysis to ensure accurate diagnosis and therapy alignment.
Eosinophilic asthma is a phenotype of asthma characterized by elevated airway eosinophilic inflammation, particularly prevalent in patients with moderate to severe and recurrent acute exacerbations. From a pharmaceutical market perspective, this field has historically relied primarily on inhaled corticosteroids, LABAs, and, when necessary, oral corticosteroids to control symptoms. In recent years, however, it has clearly entered a precision medicine phase centered on patient phenotype identification and targeted biologic therapy. This is driving the eosinophilic asthma market away from the traditional approach of "treating all asthma patients with similar pathways" towards stratified treatment based on characteristics such as eosinophil levels, FeNO, allergic status, history of acute exacerbations, and nasal polyps.
Biologics are becoming the most important driver of growth in the eosinophilic asthma market, with the IL-5/IL-5Rα pathway remaining the most direct and mature core pathway. Mepolizumab and reslizumab reduce eosinophilic inflammation by inhibiting IL-5 signaling, while benralizumab targets IL-5Rα and directly depletes eosinophils. Meanwhile, dupilumab blocks IL-4Rα, reaching a broader range of Type 2 inflammation patients, while tezepelumab intervenes from the upstream TSLP pathway, showing therapeutic value in some severe asthma patients with low eosinophil counts. Therefore, future market competition will not simply be a competition between anti-IL-5 drugs, but will evolve into a patient-stratified competition among IL-5/IL-5R, IL-4/IL-13, TSLP, and next-generation dual-target drugs. Treatment selection will increasingly rely on precise biomarkers and companion diagnostic systems.
This report is a detailed and comprehensive analysis of the world market for Eosinophilic Asthma Treatment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Eosinophilic Asthma Treatment that contribute to its increasing demand across many markets.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Eosinophilic Asthma Treatment market
2. What is the demand of the global Eosinophilic Asthma Treatment market?
3. What is the year over year growth of the global Eosinophilic Asthma Treatment market?
4. What is the total value of the global Eosinophilic Asthma Treatment market?
5. Who are the Major Players in the global Eosinophilic Asthma Treatment market?
6. What are the growth factors driving the market demand?
Eosinophilic asthma treatment focuses on managing a severe subtype of asthma characterized by elevated levels of eosinophils, a type of white blood cell that contributes to inflammation in the airways. Traditional therapies, such as inhaled corticosteroids and bronchodilators, often prove insufficient for patients with this phenotype. Monoclonal antibodies such as mepolizumab, reslizumab, and benralizumab target interleukin-5 (IL-5) or its receptor, effectively reducing eosinophil levels and decreasing the frequency of exacerbations. The management strategy also includes identifying eosinophilic biomarkers through blood tests or sputum analysis to ensure accurate diagnosis and therapy alignment.
Eosinophilic asthma is a phenotype of asthma characterized by elevated airway eosinophilic inflammation, particularly prevalent in patients with moderate to severe and recurrent acute exacerbations. From a pharmaceutical market perspective, this field has historically relied primarily on inhaled corticosteroids, LABAs, and, when necessary, oral corticosteroids to control symptoms. In recent years, however, it has clearly entered a precision medicine phase centered on patient phenotype identification and targeted biologic therapy. This is driving the eosinophilic asthma market away from the traditional approach of "treating all asthma patients with similar pathways" towards stratified treatment based on characteristics such as eosinophil levels, FeNO, allergic status, history of acute exacerbations, and nasal polyps.
Biologics are becoming the most important driver of growth in the eosinophilic asthma market, with the IL-5/IL-5Rα pathway remaining the most direct and mature core pathway. Mepolizumab and reslizumab reduce eosinophilic inflammation by inhibiting IL-5 signaling, while benralizumab targets IL-5Rα and directly depletes eosinophils. Meanwhile, dupilumab blocks IL-4Rα, reaching a broader range of Type 2 inflammation patients, while tezepelumab intervenes from the upstream TSLP pathway, showing therapeutic value in some severe asthma patients with low eosinophil counts. Therefore, future market competition will not simply be a competition between anti-IL-5 drugs, but will evolve into a patient-stratified competition among IL-5/IL-5R, IL-4/IL-13, TSLP, and next-generation dual-target drugs. Treatment selection will increasingly rely on precise biomarkers and companion diagnostic systems.
Report Scope
This report studies the global Eosinophilic Asthma Treatment demand, key companies, and key regions.This report is a detailed and comprehensive analysis of the world market for Eosinophilic Asthma Treatment, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Eosinophilic Asthma Treatment that contribute to its increasing demand across many markets.
Highlights and key features of the study
- Global Eosinophilic Asthma Treatment total market, 2021-2032, (USD Million)
- Global Eosinophilic Asthma Treatment total market by region & country, CAGR, 2021-2032, (USD Million)
- U.S. VS China: Eosinophilic Asthma Treatment total market, key domestic companies, and share, (USD Million)
- Global Eosinophilic Asthma Treatment revenue by player, revenue and market share 2021-2026, (USD Million)
- Global Eosinophilic Asthma Treatment total market by Type, CAGR, 2021-2032, (USD Million)
- Global Eosinophilic Asthma Treatment total market by Application, CAGR, 2021-2032, (USD Million)
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Eosinophilic Asthma Treatment market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.Global Eosinophilic Asthma Treatment Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
Market Segmentation
Global Eosinophilic Asthma Treatment Market, Segmentation by Type:
- Intravenous Infusion
- Subcutaneous Injection
Global Eosinophilic Asthma Treatment Market, Segmentation by Target:
- Anti-IL-5
- Anti-IL-5Rα
- Anti-IL-4Rα
- Anti-TSLP
- Others
Global Eosinophilic Asthma Treatment Market, Segmentation by Disease Severity:
- Severe Eosinophilic Asthma
- Moderate-to-Severe Eosinophilic Asthma
- Others
Global Eosinophilic Asthma Treatment Market, Segmentation by Application:
- Children
- Adults
- Teenagers
Companies Profiled:
- AstraZeneca
- GSK
- Genentech (Roche Group) & Novartis
- Regeneron Pharmaceuticals & Sanofi
- Teva Pharmaceuticals
- Amgen
- Sunshine Guojian
- Hengrui Pharma
Key Questions Answered
1. How big is the global Eosinophilic Asthma Treatment market?2. What is the demand of the global Eosinophilic Asthma Treatment market?
3. What is the year over year growth of the global Eosinophilic Asthma Treatment market?
4. What is the total value of the global Eosinophilic Asthma Treatment market?
5. Who are the Major Players in the global Eosinophilic Asthma Treatment market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Eosinophilic Asthma Treatment Introduction
1.2 World Eosinophilic Asthma Treatment Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Eosinophilic Asthma Treatment Total Market by Region (by Headquarter Location)
1.3.1 World Eosinophilic Asthma Treatment Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.3.3 China Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.3.4 Europe Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.3.5 Japan Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.3.6 South Korea Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.3.7 ASEAN Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.3.8 India Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Eosinophilic Asthma Treatment Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.2 World Eosinophilic Asthma Treatment Consumption Value by Region
2.2.1 World Eosinophilic Asthma Treatment Consumption Value by Region (2021-2026)
2.2.2 World Eosinophilic Asthma Treatment Consumption Value Forecast by Region (2027-2032)
2.3 United States Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.4 China Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.5 Europe Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.6 Japan Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.7 South Korea Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.8 ASEAN Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.9 India Eosinophilic Asthma Treatment Consumption Value (2021-2032)
3 WORLD EOSINOPHILIC ASTHMA TREATMENT COMPANIES COMPETITIVE ANALYSIS
3.1 World Eosinophilic Asthma Treatment Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Eosinophilic Asthma Treatment Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Eosinophilic Asthma Treatment in 2025
3.2.3 Global Concentration Ratios (CR8) for Eosinophilic Asthma Treatment in 2025
3.3 Eosinophilic Asthma Treatment Company Evaluation Quadrant
3.4 Eosinophilic Asthma Treatment Market: Overall Company Footprint Analysis
3.4.1 Eosinophilic Asthma Treatment Market: Region Footprint
3.4.2 Eosinophilic Asthma Treatment Market: Company Product Type Footprint
3.4.3 Eosinophilic Asthma Treatment Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Eosinophilic Asthma Treatment Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Eosinophilic Asthma Treatment Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Eosinophilic Asthma Treatment Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Eosinophilic Asthma Treatment Consumption Value Comparison
4.2.1 United States VS China: Eosinophilic Asthma Treatment Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Eosinophilic Asthma Treatment Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Eosinophilic Asthma Treatment Companies and Market Share, 2021-2026
4.3.1 United States Based Eosinophilic Asthma Treatment Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Eosinophilic Asthma Treatment Revenue, (2021-2026)
4.4 China Based Companies Eosinophilic Asthma Treatment Revenue and Market Share, 2021-2026
4.4.1 China Based Eosinophilic Asthma Treatment Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Eosinophilic Asthma Treatment Revenue, (2021-2026)
4.5 Rest of World Based Eosinophilic Asthma Treatment Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Eosinophilic Asthma Treatment Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Eosinophilic Asthma Treatment Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Eosinophilic Asthma Treatment Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Intravenous Infusion
5.2.2 Subcutaneous Injection
5.3 Market Segment by Type
5.3.1 World Eosinophilic Asthma Treatment Market Size by Type (2021-2026)
5.3.2 World Eosinophilic Asthma Treatment Market Size by Type (2027-2032)
5.3.3 World Eosinophilic Asthma Treatment Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY TARGET
6.1 World Eosinophilic Asthma Treatment Market Size Overview by Target: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Target
6.2.1 Anti-IL-5
6.2.2 Anti-IL-5Rα
6.2.3 Anti-IL-4Rα
6.2.4 Anti-TSLP
6.2.5 Others
6.3 Market Segment by Target
6.3.1 World Eosinophilic Asthma Treatment Market Size by Target (2021-2026)
6.3.2 World Eosinophilic Asthma Treatment Market Size by Target (2027-2032)
6.3.3 World Eosinophilic Asthma Treatment Market Size Market Share by Target (2027-2032)
7 MARKET ANALYSIS BY DISEASE SEVERITY
7.1 World Eosinophilic Asthma Treatment Market Size Overview by Disease Severity: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Disease Severity
7.2.1 Severe Eosinophilic Asthma
7.2.2 Moderate-to-Severe Eosinophilic Asthma
7.2.3 Others
7.3 Market Segment by Disease Severity
7.3.1 World Eosinophilic Asthma Treatment Market Size by Disease Severity (2021-2026)
7.3.2 World Eosinophilic Asthma Treatment Market Size by Disease Severity (2027-2032)
7.3.3 World Eosinophilic Asthma Treatment Market Size Market Share by Disease Severity (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Eosinophilic Asthma Treatment Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Children
8.2.2 Adults
8.2.3 Teenagers
8.3 Market Segment by Application
8.3.1 World Eosinophilic Asthma Treatment Market Size by Application (2021-2026)
8.3.2 World Eosinophilic Asthma Treatment Market Size by Application (2027-2032)
8.3.3 World Eosinophilic Asthma Treatment Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 AstraZeneca
9.1.1 AstraZeneca Details
9.1.2 AstraZeneca Major Business
9.1.3 AstraZeneca Eosinophilic Asthma Treatment Product and Services
9.1.4 AstraZeneca Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 AstraZeneca Recent Developments/Updates
9.1.6 AstraZeneca Competitive Strengths & Weaknesses
9.2 GSK
9.2.1 GSK Details
9.2.2 GSK Major Business
9.2.3 GSK Eosinophilic Asthma Treatment Product and Services
9.2.4 GSK Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 GSK Recent Developments/Updates
9.2.6 GSK Competitive Strengths & Weaknesses
9.3 Genentech (Roche Group) & Novartis
9.3.1 Genentech (Roche Group) & Novartis Details
9.3.2 Genentech (Roche Group) & Novartis Major Business
9.3.3 Genentech (Roche Group) & Novartis Eosinophilic Asthma Treatment Product and Services
9.3.4 Genentech (Roche Group) & Novartis Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Genentech (Roche Group) & Novartis Recent Developments/Updates
9.3.6 Genentech (Roche Group) & Novartis Competitive Strengths & Weaknesses
9.4 Regeneron Pharmaceuticals & Sanofi
9.4.1 Regeneron Pharmaceuticals & Sanofi Details
9.4.2 Regeneron Pharmaceuticals & Sanofi Major Business
9.4.3 Regeneron Pharmaceuticals & Sanofi Eosinophilic Asthma Treatment Product and Services
9.4.4 Regeneron Pharmaceuticals & Sanofi Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Regeneron Pharmaceuticals & Sanofi Recent Developments/Updates
9.4.6 Regeneron Pharmaceuticals & Sanofi Competitive Strengths & Weaknesses
9.5 Teva Pharmaceuticals
9.5.1 Teva Pharmaceuticals Details
9.5.2 Teva Pharmaceuticals Major Business
9.5.3 Teva Pharmaceuticals Eosinophilic Asthma Treatment Product and Services
9.5.4 Teva Pharmaceuticals Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Teva Pharmaceuticals Recent Developments/Updates
9.5.6 Teva Pharmaceuticals Competitive Strengths & Weaknesses
9.6 Amgen
9.6.1 Amgen Details
9.6.2 Amgen Major Business
9.6.3 Amgen Eosinophilic Asthma Treatment Product and Services
9.6.4 Amgen Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Amgen Recent Developments/Updates
9.6.6 Amgen Competitive Strengths & Weaknesses
9.7 Sunshine Guojian
9.7.1 Sunshine Guojian Details
9.7.2 Sunshine Guojian Major Business
9.7.3 Sunshine Guojian Eosinophilic Asthma Treatment Product and Services
9.7.4 Sunshine Guojian Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Sunshine Guojian Recent Developments/Updates
9.7.6 Sunshine Guojian Competitive Strengths & Weaknesses
9.8 Hengrui Pharma
9.8.1 Hengrui Pharma Details
9.8.2 Hengrui Pharma Major Business
9.8.3 Hengrui Pharma Eosinophilic Asthma Treatment Product and Services
9.8.4 Hengrui Pharma Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Hengrui Pharma Recent Developments/Updates
9.8.6 Hengrui Pharma Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Eosinophilic Asthma Treatment Industry Chain
10.2 Eosinophilic Asthma Treatment Upstream Analysis
10.3 Eosinophilic Asthma Treatment Midstream Analysis
10.4 Eosinophilic Asthma Treatment Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Eosinophilic Asthma Treatment Introduction
1.2 World Eosinophilic Asthma Treatment Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Eosinophilic Asthma Treatment Total Market by Region (by Headquarter Location)
1.3.1 World Eosinophilic Asthma Treatment Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.3.3 China Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.3.4 Europe Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.3.5 Japan Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.3.6 South Korea Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.3.7 ASEAN Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.3.8 India Based Company Eosinophilic Asthma Treatment Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Eosinophilic Asthma Treatment Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.2 World Eosinophilic Asthma Treatment Consumption Value by Region
2.2.1 World Eosinophilic Asthma Treatment Consumption Value by Region (2021-2026)
2.2.2 World Eosinophilic Asthma Treatment Consumption Value Forecast by Region (2027-2032)
2.3 United States Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.4 China Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.5 Europe Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.6 Japan Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.7 South Korea Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.8 ASEAN Eosinophilic Asthma Treatment Consumption Value (2021-2032)
2.9 India Eosinophilic Asthma Treatment Consumption Value (2021-2032)
3 WORLD EOSINOPHILIC ASTHMA TREATMENT COMPANIES COMPETITIVE ANALYSIS
3.1 World Eosinophilic Asthma Treatment Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Eosinophilic Asthma Treatment Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Eosinophilic Asthma Treatment in 2025
3.2.3 Global Concentration Ratios (CR8) for Eosinophilic Asthma Treatment in 2025
3.3 Eosinophilic Asthma Treatment Company Evaluation Quadrant
3.4 Eosinophilic Asthma Treatment Market: Overall Company Footprint Analysis
3.4.1 Eosinophilic Asthma Treatment Market: Region Footprint
3.4.2 Eosinophilic Asthma Treatment Market: Company Product Type Footprint
3.4.3 Eosinophilic Asthma Treatment Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Eosinophilic Asthma Treatment Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Eosinophilic Asthma Treatment Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Eosinophilic Asthma Treatment Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Eosinophilic Asthma Treatment Consumption Value Comparison
4.2.1 United States VS China: Eosinophilic Asthma Treatment Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Eosinophilic Asthma Treatment Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Eosinophilic Asthma Treatment Companies and Market Share, 2021-2026
4.3.1 United States Based Eosinophilic Asthma Treatment Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Eosinophilic Asthma Treatment Revenue, (2021-2026)
4.4 China Based Companies Eosinophilic Asthma Treatment Revenue and Market Share, 2021-2026
4.4.1 China Based Eosinophilic Asthma Treatment Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Eosinophilic Asthma Treatment Revenue, (2021-2026)
4.5 Rest of World Based Eosinophilic Asthma Treatment Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Eosinophilic Asthma Treatment Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Eosinophilic Asthma Treatment Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Eosinophilic Asthma Treatment Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Intravenous Infusion
5.2.2 Subcutaneous Injection
5.3 Market Segment by Type
5.3.1 World Eosinophilic Asthma Treatment Market Size by Type (2021-2026)
5.3.2 World Eosinophilic Asthma Treatment Market Size by Type (2027-2032)
5.3.3 World Eosinophilic Asthma Treatment Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY TARGET
6.1 World Eosinophilic Asthma Treatment Market Size Overview by Target: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Target
6.2.1 Anti-IL-5
6.2.2 Anti-IL-5Rα
6.2.3 Anti-IL-4Rα
6.2.4 Anti-TSLP
6.2.5 Others
6.3 Market Segment by Target
6.3.1 World Eosinophilic Asthma Treatment Market Size by Target (2021-2026)
6.3.2 World Eosinophilic Asthma Treatment Market Size by Target (2027-2032)
6.3.3 World Eosinophilic Asthma Treatment Market Size Market Share by Target (2027-2032)
7 MARKET ANALYSIS BY DISEASE SEVERITY
7.1 World Eosinophilic Asthma Treatment Market Size Overview by Disease Severity: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Disease Severity
7.2.1 Severe Eosinophilic Asthma
7.2.2 Moderate-to-Severe Eosinophilic Asthma
7.2.3 Others
7.3 Market Segment by Disease Severity
7.3.1 World Eosinophilic Asthma Treatment Market Size by Disease Severity (2021-2026)
7.3.2 World Eosinophilic Asthma Treatment Market Size by Disease Severity (2027-2032)
7.3.3 World Eosinophilic Asthma Treatment Market Size Market Share by Disease Severity (2027-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Eosinophilic Asthma Treatment Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Children
8.2.2 Adults
8.2.3 Teenagers
8.3 Market Segment by Application
8.3.1 World Eosinophilic Asthma Treatment Market Size by Application (2021-2026)
8.3.2 World Eosinophilic Asthma Treatment Market Size by Application (2027-2032)
8.3.3 World Eosinophilic Asthma Treatment Market Size Market Share by Application (2021-2032)
9 COMPANY PROFILES
9.1 AstraZeneca
9.1.1 AstraZeneca Details
9.1.2 AstraZeneca Major Business
9.1.3 AstraZeneca Eosinophilic Asthma Treatment Product and Services
9.1.4 AstraZeneca Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 AstraZeneca Recent Developments/Updates
9.1.6 AstraZeneca Competitive Strengths & Weaknesses
9.2 GSK
9.2.1 GSK Details
9.2.2 GSK Major Business
9.2.3 GSK Eosinophilic Asthma Treatment Product and Services
9.2.4 GSK Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 GSK Recent Developments/Updates
9.2.6 GSK Competitive Strengths & Weaknesses
9.3 Genentech (Roche Group) & Novartis
9.3.1 Genentech (Roche Group) & Novartis Details
9.3.2 Genentech (Roche Group) & Novartis Major Business
9.3.3 Genentech (Roche Group) & Novartis Eosinophilic Asthma Treatment Product and Services
9.3.4 Genentech (Roche Group) & Novartis Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Genentech (Roche Group) & Novartis Recent Developments/Updates
9.3.6 Genentech (Roche Group) & Novartis Competitive Strengths & Weaknesses
9.4 Regeneron Pharmaceuticals & Sanofi
9.4.1 Regeneron Pharmaceuticals & Sanofi Details
9.4.2 Regeneron Pharmaceuticals & Sanofi Major Business
9.4.3 Regeneron Pharmaceuticals & Sanofi Eosinophilic Asthma Treatment Product and Services
9.4.4 Regeneron Pharmaceuticals & Sanofi Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Regeneron Pharmaceuticals & Sanofi Recent Developments/Updates
9.4.6 Regeneron Pharmaceuticals & Sanofi Competitive Strengths & Weaknesses
9.5 Teva Pharmaceuticals
9.5.1 Teva Pharmaceuticals Details
9.5.2 Teva Pharmaceuticals Major Business
9.5.3 Teva Pharmaceuticals Eosinophilic Asthma Treatment Product and Services
9.5.4 Teva Pharmaceuticals Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 Teva Pharmaceuticals Recent Developments/Updates
9.5.6 Teva Pharmaceuticals Competitive Strengths & Weaknesses
9.6 Amgen
9.6.1 Amgen Details
9.6.2 Amgen Major Business
9.6.3 Amgen Eosinophilic Asthma Treatment Product and Services
9.6.4 Amgen Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Amgen Recent Developments/Updates
9.6.6 Amgen Competitive Strengths & Weaknesses
9.7 Sunshine Guojian
9.7.1 Sunshine Guojian Details
9.7.2 Sunshine Guojian Major Business
9.7.3 Sunshine Guojian Eosinophilic Asthma Treatment Product and Services
9.7.4 Sunshine Guojian Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Sunshine Guojian Recent Developments/Updates
9.7.6 Sunshine Guojian Competitive Strengths & Weaknesses
9.8 Hengrui Pharma
9.8.1 Hengrui Pharma Details
9.8.2 Hengrui Pharma Major Business
9.8.3 Hengrui Pharma Eosinophilic Asthma Treatment Product and Services
9.8.4 Hengrui Pharma Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Hengrui Pharma Recent Developments/Updates
9.8.6 Hengrui Pharma Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Eosinophilic Asthma Treatment Industry Chain
10.2 Eosinophilic Asthma Treatment Upstream Analysis
10.3 Eosinophilic Asthma Treatment Midstream Analysis
10.4 Eosinophilic Asthma Treatment Downstream Analysis
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Eosinophilic Asthma Treatment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Eosinophilic Asthma Treatment Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Eosinophilic Asthma Treatment Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Eosinophilic Asthma Treatment Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Eosinophilic Asthma Treatment Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Eosinophilic Asthma Treatment Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Eosinophilic Asthma Treatment Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Eosinophilic Asthma Treatment Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Eosinophilic Asthma Treatment Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Eosinophilic Asthma Treatment Players in 2025
Table 12. World Eosinophilic Asthma Treatment Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Eosinophilic Asthma Treatment Company Evaluation Quadrant
Table 14. Head Office of Key Eosinophilic Asthma Treatment Players
Table 15. Eosinophilic Asthma Treatment Market: Company Product Type Footprint
Table 16. Eosinophilic Asthma Treatment Market: Company Product Application Footprint
Table 17. Eosinophilic Asthma Treatment Mergers & Acquisitions Activity
Table 18. United States VS China Eosinophilic Asthma Treatment Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Eosinophilic Asthma Treatment Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Eosinophilic Asthma Treatment Companies, Headquarters (States, Country)
Table 21. United States Based Companies Eosinophilic Asthma Treatment Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Eosinophilic Asthma Treatment Revenue Market Share (2021-2026)
Table 23. China Based Eosinophilic Asthma Treatment Companies, Headquarters (Province, Country)
Table 24. China Based Companies Eosinophilic Asthma Treatment Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Eosinophilic Asthma Treatment Revenue Market Share (2021-2026)
Table 26. Rest of World Based Eosinophilic Asthma Treatment Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Eosinophilic Asthma Treatment Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Eosinophilic Asthma Treatment Revenue Market Share (2021-2026)
Table 29. World Eosinophilic Asthma Treatment Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Eosinophilic Asthma Treatment Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Eosinophilic Asthma Treatment Market Size by Type (2027-2032) & (USD Million)
Table 32. World Eosinophilic Asthma Treatment Market Size by Target, (USD Million), 2021 & 2025 & 2032
Table 33. World Eosinophilic Asthma Treatment Market Size Value by Target (2021-2026) & (USD Million)
Table 34. World Eosinophilic Asthma Treatment Market Size by Target (2027-2032) & (USD Million)
Table 35. World Eosinophilic Asthma Treatment Market Size by Disease Severity, (USD Million), 2021 & 2025 & 2032
Table 36. World Eosinophilic Asthma Treatment Market Size Value by Disease Severity (2021-2026) & (USD Million)
Table 37. World Eosinophilic Asthma Treatment Market Size by Disease Severity (2027-2032) & (USD Million)
Table 38. World Eosinophilic Asthma Treatment Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Eosinophilic Asthma Treatment Market Size by Application (2021-2026) & (USD Million)
Table 40. World Eosinophilic Asthma Treatment Market Size by Application (2027-2032) & (USD Million)
Table 41. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 42. AstraZeneca Major Business
Table 43. AstraZeneca Eosinophilic Asthma Treatment Product and Services
Table 44. AstraZeneca Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. AstraZeneca Recent Developments/Updates
Table 46. AstraZeneca Competitive Strengths & Weaknesses
Table 47. GSK Basic Information, Manufacturing Base and Competitors
Table 48. GSK Major Business
Table 49. GSK Eosinophilic Asthma Treatment Product and Services
Table 50. GSK Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. GSK Recent Developments/Updates
Table 52. GSK Competitive Strengths & Weaknesses
Table 53. Genentech (Roche Group) & Novartis Basic Information, Manufacturing Base and Competitors
Table 54. Genentech (Roche Group) & Novartis Major Business
Table 55. Genentech (Roche Group) & Novartis Eosinophilic Asthma Treatment Product and Services
Table 56. Genentech (Roche Group) & Novartis Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Genentech (Roche Group) & Novartis Recent Developments/Updates
Table 58. Genentech (Roche Group) & Novartis Competitive Strengths & Weaknesses
Table 59. Regeneron Pharmaceuticals & Sanofi Basic Information, Manufacturing Base and Competitors
Table 60. Regeneron Pharmaceuticals & Sanofi Major Business
Table 61. Regeneron Pharmaceuticals & Sanofi Eosinophilic Asthma Treatment Product and Services
Table 62. Regeneron Pharmaceuticals & Sanofi Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Regeneron Pharmaceuticals & Sanofi Recent Developments/Updates
Table 64. Regeneron Pharmaceuticals & Sanofi Competitive Strengths & Weaknesses
Table 65. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 66. Teva Pharmaceuticals Major Business
Table 67. Teva Pharmaceuticals Eosinophilic Asthma Treatment Product and Services
Table 68. Teva Pharmaceuticals Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Teva Pharmaceuticals Recent Developments/Updates
Table 70. Teva Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Amgen Basic Information, Manufacturing Base and Competitors
Table 72. Amgen Major Business
Table 73. Amgen Eosinophilic Asthma Treatment Product and Services
Table 74. Amgen Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Amgen Recent Developments/Updates
Table 76. Amgen Competitive Strengths & Weaknesses
Table 77. Sunshine Guojian Basic Information, Manufacturing Base and Competitors
Table 78. Sunshine Guojian Major Business
Table 79. Sunshine Guojian Eosinophilic Asthma Treatment Product and Services
Table 80. Sunshine Guojian Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Sunshine Guojian Recent Developments/Updates
Table 82. Sunshine Guojian Competitive Strengths & Weaknesses
Table 83. Hengrui Pharma Basic Information, Manufacturing Base and Competitors
Table 84. Hengrui Pharma Major Business
Table 85. Hengrui Pharma Eosinophilic Asthma Treatment Product and Services
Table 86. Hengrui Pharma Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Hengrui Pharma Recent Developments/Updates
Table 88. Hengrui Pharma Competitive Strengths & Weaknesses
Table 89. Global Key Players of Eosinophilic Asthma Treatment Upstream (Raw Materials)
Table 90. Global Eosinophilic Asthma Treatment Typical Customers
Table 1. World Eosinophilic Asthma Treatment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Eosinophilic Asthma Treatment Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Eosinophilic Asthma Treatment Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Eosinophilic Asthma Treatment Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Eosinophilic Asthma Treatment Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Eosinophilic Asthma Treatment Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Eosinophilic Asthma Treatment Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Eosinophilic Asthma Treatment Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Eosinophilic Asthma Treatment Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Eosinophilic Asthma Treatment Players in 2025
Table 12. World Eosinophilic Asthma Treatment Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Eosinophilic Asthma Treatment Company Evaluation Quadrant
Table 14. Head Office of Key Eosinophilic Asthma Treatment Players
Table 15. Eosinophilic Asthma Treatment Market: Company Product Type Footprint
Table 16. Eosinophilic Asthma Treatment Market: Company Product Application Footprint
Table 17. Eosinophilic Asthma Treatment Mergers & Acquisitions Activity
Table 18. United States VS China Eosinophilic Asthma Treatment Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Eosinophilic Asthma Treatment Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Eosinophilic Asthma Treatment Companies, Headquarters (States, Country)
Table 21. United States Based Companies Eosinophilic Asthma Treatment Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Eosinophilic Asthma Treatment Revenue Market Share (2021-2026)
Table 23. China Based Eosinophilic Asthma Treatment Companies, Headquarters (Province, Country)
Table 24. China Based Companies Eosinophilic Asthma Treatment Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Eosinophilic Asthma Treatment Revenue Market Share (2021-2026)
Table 26. Rest of World Based Eosinophilic Asthma Treatment Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Eosinophilic Asthma Treatment Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Eosinophilic Asthma Treatment Revenue Market Share (2021-2026)
Table 29. World Eosinophilic Asthma Treatment Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Eosinophilic Asthma Treatment Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Eosinophilic Asthma Treatment Market Size by Type (2027-2032) & (USD Million)
Table 32. World Eosinophilic Asthma Treatment Market Size by Target, (USD Million), 2021 & 2025 & 2032
Table 33. World Eosinophilic Asthma Treatment Market Size Value by Target (2021-2026) & (USD Million)
Table 34. World Eosinophilic Asthma Treatment Market Size by Target (2027-2032) & (USD Million)
Table 35. World Eosinophilic Asthma Treatment Market Size by Disease Severity, (USD Million), 2021 & 2025 & 2032
Table 36. World Eosinophilic Asthma Treatment Market Size Value by Disease Severity (2021-2026) & (USD Million)
Table 37. World Eosinophilic Asthma Treatment Market Size by Disease Severity (2027-2032) & (USD Million)
Table 38. World Eosinophilic Asthma Treatment Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Eosinophilic Asthma Treatment Market Size by Application (2021-2026) & (USD Million)
Table 40. World Eosinophilic Asthma Treatment Market Size by Application (2027-2032) & (USD Million)
Table 41. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 42. AstraZeneca Major Business
Table 43. AstraZeneca Eosinophilic Asthma Treatment Product and Services
Table 44. AstraZeneca Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. AstraZeneca Recent Developments/Updates
Table 46. AstraZeneca Competitive Strengths & Weaknesses
Table 47. GSK Basic Information, Manufacturing Base and Competitors
Table 48. GSK Major Business
Table 49. GSK Eosinophilic Asthma Treatment Product and Services
Table 50. GSK Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. GSK Recent Developments/Updates
Table 52. GSK Competitive Strengths & Weaknesses
Table 53. Genentech (Roche Group) & Novartis Basic Information, Manufacturing Base and Competitors
Table 54. Genentech (Roche Group) & Novartis Major Business
Table 55. Genentech (Roche Group) & Novartis Eosinophilic Asthma Treatment Product and Services
Table 56. Genentech (Roche Group) & Novartis Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Genentech (Roche Group) & Novartis Recent Developments/Updates
Table 58. Genentech (Roche Group) & Novartis Competitive Strengths & Weaknesses
Table 59. Regeneron Pharmaceuticals & Sanofi Basic Information, Manufacturing Base and Competitors
Table 60. Regeneron Pharmaceuticals & Sanofi Major Business
Table 61. Regeneron Pharmaceuticals & Sanofi Eosinophilic Asthma Treatment Product and Services
Table 62. Regeneron Pharmaceuticals & Sanofi Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Regeneron Pharmaceuticals & Sanofi Recent Developments/Updates
Table 64. Regeneron Pharmaceuticals & Sanofi Competitive Strengths & Weaknesses
Table 65. Teva Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 66. Teva Pharmaceuticals Major Business
Table 67. Teva Pharmaceuticals Eosinophilic Asthma Treatment Product and Services
Table 68. Teva Pharmaceuticals Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Teva Pharmaceuticals Recent Developments/Updates
Table 70. Teva Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Amgen Basic Information, Manufacturing Base and Competitors
Table 72. Amgen Major Business
Table 73. Amgen Eosinophilic Asthma Treatment Product and Services
Table 74. Amgen Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Amgen Recent Developments/Updates
Table 76. Amgen Competitive Strengths & Weaknesses
Table 77. Sunshine Guojian Basic Information, Manufacturing Base and Competitors
Table 78. Sunshine Guojian Major Business
Table 79. Sunshine Guojian Eosinophilic Asthma Treatment Product and Services
Table 80. Sunshine Guojian Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Sunshine Guojian Recent Developments/Updates
Table 82. Sunshine Guojian Competitive Strengths & Weaknesses
Table 83. Hengrui Pharma Basic Information, Manufacturing Base and Competitors
Table 84. Hengrui Pharma Major Business
Table 85. Hengrui Pharma Eosinophilic Asthma Treatment Product and Services
Table 86. Hengrui Pharma Eosinophilic Asthma Treatment Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Hengrui Pharma Recent Developments/Updates
Table 88. Hengrui Pharma Competitive Strengths & Weaknesses
Table 89. Global Key Players of Eosinophilic Asthma Treatment Upstream (Raw Materials)
Table 90. Global Eosinophilic Asthma Treatment Typical Customers
LIST OF FIGURES
Figure 1. Eosinophilic Asthma Treatment Picture
Figure 2. World Eosinophilic Asthma Treatment Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Eosinophilic Asthma Treatment Total Revenue (2021-2032) & (USD Million)
Figure 4. World Eosinophilic Asthma Treatment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Eosinophilic Asthma Treatment Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 13. Eosinophilic Asthma Treatment Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 16. World Eosinophilic Asthma Treatment Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 18. China Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 23. India Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Eosinophilic Asthma Treatment by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Eosinophilic Asthma Treatment Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Eosinophilic Asthma Treatment Markets in 2025
Figure 27. United States VS China: Eosinophilic Asthma Treatment Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Eosinophilic Asthma Treatment Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Eosinophilic Asthma Treatment Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Eosinophilic Asthma Treatment Market Size Market Share by Type in 2025
Figure 31. Intravenous Infusion
Figure 32. Subcutaneous Injection
Figure 33. World Eosinophilic Asthma Treatment Market Size Market Share by Type (2021-2032)
Figure 34. World Eosinophilic Asthma Treatment Market Size by Target, (USD Million), 2021 & 2025 & 2032
Figure 35. World Eosinophilic Asthma Treatment Market Size Market Share by Target in 2025
Figure 36. Anti-IL-5
Figure 37. Anti-IL-5Rα
Figure 38. Anti-IL-4Rα
Figure 39. Anti-TSLP
Figure 40. Others
Figure 41. World Eosinophilic Asthma Treatment Market Size Market Share by Target (2021-2032)
Figure 42. World Eosinophilic Asthma Treatment Market Size by Disease Severity, (USD Million), 2021 & 2025 & 2032
Figure 43. World Eosinophilic Asthma Treatment Market Size Market Share by Disease Severity in 2025
Figure 44. Severe Eosinophilic Asthma
Figure 45. Moderate-to-Severe Eosinophilic Asthma
Figure 46. Others
Figure 47. World Eosinophilic Asthma Treatment Market Size Market Share by Disease Severity (2021-2032)
Figure 48. World Eosinophilic Asthma Treatment Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 49. World Eosinophilic Asthma Treatment Market Size Market Share by Application in 2025
Figure 50. Children
Figure 51. Adults
Figure 52. Teenagers
Figure 53. World Eosinophilic Asthma Treatment Market Size Market Share by Application (2021-2032)
Figure 54. Eosinophilic Asthma Treatment Industrial Chain
Figure 55. Methodology
Figure 56. Research Process and Data Source
Figure 1. Eosinophilic Asthma Treatment Picture
Figure 2. World Eosinophilic Asthma Treatment Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Eosinophilic Asthma Treatment Total Revenue (2021-2032) & (USD Million)
Figure 4. World Eosinophilic Asthma Treatment Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Eosinophilic Asthma Treatment Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Eosinophilic Asthma Treatment Revenue (2021-2032) & (USD Million)
Figure 13. Eosinophilic Asthma Treatment Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 16. World Eosinophilic Asthma Treatment Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 18. China Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 23. India Eosinophilic Asthma Treatment Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Eosinophilic Asthma Treatment by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Eosinophilic Asthma Treatment Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Eosinophilic Asthma Treatment Markets in 2025
Figure 27. United States VS China: Eosinophilic Asthma Treatment Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Eosinophilic Asthma Treatment Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Eosinophilic Asthma Treatment Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Eosinophilic Asthma Treatment Market Size Market Share by Type in 2025
Figure 31. Intravenous Infusion
Figure 32. Subcutaneous Injection
Figure 33. World Eosinophilic Asthma Treatment Market Size Market Share by Type (2021-2032)
Figure 34. World Eosinophilic Asthma Treatment Market Size by Target, (USD Million), 2021 & 2025 & 2032
Figure 35. World Eosinophilic Asthma Treatment Market Size Market Share by Target in 2025
Figure 36. Anti-IL-5
Figure 37. Anti-IL-5Rα
Figure 38. Anti-IL-4Rα
Figure 39. Anti-TSLP
Figure 40. Others
Figure 41. World Eosinophilic Asthma Treatment Market Size Market Share by Target (2021-2032)
Figure 42. World Eosinophilic Asthma Treatment Market Size by Disease Severity, (USD Million), 2021 & 2025 & 2032
Figure 43. World Eosinophilic Asthma Treatment Market Size Market Share by Disease Severity in 2025
Figure 44. Severe Eosinophilic Asthma
Figure 45. Moderate-to-Severe Eosinophilic Asthma
Figure 46. Others
Figure 47. World Eosinophilic Asthma Treatment Market Size Market Share by Disease Severity (2021-2032)
Figure 48. World Eosinophilic Asthma Treatment Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 49. World Eosinophilic Asthma Treatment Market Size Market Share by Application in 2025
Figure 50. Children
Figure 51. Adults
Figure 52. Teenagers
Figure 53. World Eosinophilic Asthma Treatment Market Size Market Share by Application (2021-2032)
Figure 54. Eosinophilic Asthma Treatment Industrial Chain
Figure 55. Methodology
Figure 56. Research Process and Data Source